Enavatuzumab
Cat. No.: A563
Featured
Chemical Structure
1062149-33-0
We are official vendor of:
More than 5000 active chemicals with high quality for research!
Field of application
Enavatuzumab (PDL192; ABT-361) is a humanized IgG1 monoclonal antibody targeting the receptor of TNF-like weak inducer of apoptosis (TWEAK). TWEAK (Fn14; TNFRSF12A), the natural ligand of the TWEAK receptor (TweakR), stimulates multiple cellular responses. Enavatuzumab induces tumor growth inhibition through direct TweakR signaling and antibody dependent cell-mediated cytotoxicity (ADCC). Enavatuzumab can actively recruits and activates myeloid effectors to kill tumor cells. Enavatuzumab inhibits the growth of various human TweakR-positive cancer cell lines and xenografts in vitro and in vivo .
| Cas No.: |
1062149-33-0 |
| pH value: |
Corresponds to reference standard: PASS |
| Non-reduced CE-SDS: |
>95% |
| SEC-HPLC: |
>95% |
| Isoelectric Point: |
Corresponds to reference standard |
| Osmolality: |
Corresponds to reference standard: PASS |
| Peptide mapping: |
Corresponds to reference standard: PASS |
| N-terminal sequence: |
Corresponds to reference standard: PASS |
Get Quote
